Background: Even after achieving tremendous advances in diagnosis and treatment of rheumatoid arthritis (RA), many of the patients undergo delays in diagnosis and initiation of treatment, which leads to worsening of the condition and poor prognosis. Objective: The objective of this study was to perform a literature review to quantify the lag times in diagnosis and treatment of RA and study the reported factors associated with it. Methods: The authors searched literature published until September 2016 in electronic full-text and abstract databases and hand-searched the suitable articles. Results: The weighted average of median lag time from symptom onset to therapy was 11.79 months (12 studies, 5,512 patients, range 3.6-24.0 months). Lag1 was 3.14 months (onset of symptoms to first physician consultant; 12 studies, 6,055 patients, range 0-5.7 months); lag2 was 2.13 months (physician visit to RA specialist referral; 13 studies, 34,767 patients, range 0.5-6.6 months); lag3 was 2.91 months (consultation with rheumatologist to diagnosis; 3 studies, 563 patients, range 0-5 months), lag4 was 2.14 months (diagnosis to initiation of disease-modifying antirheumatic drug therapy; 5 studies, 30,685 patients, range 0-2.2 months). Numerous patientand physician-related factors like gender, ethnicity, primary care physician knowledge of the condition, availability of diagnostics, and so on were responsible for the delays. Conclusion: This review estimated the delay times and identified the main factors for delay in RA patients in diagnosis and initiation of treatment. A most plausible solution to this is coordinated effort by the rheumatology and primary care physicians.
Introduction
Rheumatoid arthritis (RA) follows a chronic course and invariably involves significant long-term disability and morbidity.
1,2 A diverse group of agents called disease-modifying antirheumatic drugs (DMARDs) and potent anti-inflammatory antibodies that block tumor necrosis factor are widely accepted, respectively, for slowing the progression of RA and alleviating the painful symptoms. 3, 4 Though clinically effective, these drugs become less effective in halting the long-term progression of RA if initiation of therapy is delayed. 5, 6 After onset of the symptoms, the disease progresses quickly leading to irreversible cartilage damage in <2 months. 7 This damage can only be prevented by the initiation of therapy within 2 months from the onset of symptoms. 7 Initial studies reported no such benefit; submit your manuscript | www.dovepress.com
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Barhamain et al therapy. 10 Unfortunately, the early stages of RA are characterized by nonspecific clinical signs that have been a frequent hurdle in timely initiation of the therapy. 11 A large study of 488 patients during 1950-1974 had shown that there was a median lag of 6 months between the onset of symptoms and diagnosis. 12 This has not improved even during the 1990s as 5 months lag between the onset of symptoms and diagnosis was very common. 13 Furthermore, some of the patients remain untreated for up to 10 years after the symptoms appear. 13 A recent study performed in Saudi Arabia found that patients consulted an average of 4 physicians between their first symptom of RA and final diagnosis, with a mean time from the first physician visit to final RA diagnosis of ~30 months.
14 Although patients consulted with physicians at a mean of 7 months after the onset of RA symptoms, very few subjects initially sought a consultation with rheumatologists, who were ultimately responsible for diagnosing most RA patients.
Like any other disease, the RA patient's journey involves 3 distinct stages: onset of symptoms to consultation (lag1), consultation to rheumatology referral or definite RA diagnosis (lag2), and diagnosis to proper treatment (lag3). These lag times have been of interest to rheumatologists and have been reported by numerous studies 15, 16 with some studies focusing specifically on the factors that contribute to these delays and measures undertaken to overcome these.
In this review, we examined the literature to study the lag times in RA patients with an aim to summarize the findings for future reference. Further analysis of factors was also undertaken to understand the reasons for these lags.
Methods
The primary objective of this study was to review the reported delay in the duration (lag time) between symptom onset and initial physician visit, an initial visit to rheumatology referral, referral to diagnosis and diagnosis to proper treatment.
Secondary objectives are to review the significance of reported factors that may have contributed to delayed RA diagnosis, and the possible measures that could be taken to accelerate RA diagnosis and early initiation of treatment.
A systematic search of OVID and PubMed databases was conducted in March 2016 to identify all the data related to the journey of RA patients. In addition, Annals of Rheumatic Diseases, American College of Rheumatology Conference Index, and European League Against Rheumatism Conference Index were searched for relevant abstracts that are not published elsewhere. . All the search terms were "exploded" in conjunction with using a keyword search. The search was conducted on March 31, 2016, and was limited to English language papers.
Included databases were distributed among authors and were searched independently using the above keywords. In each database, all the search results were reviewed and papers were checked for their relevance to our primary and secondary objectives based on their title, abstract, and manuscript. Papers that were not related to our objectives were excluded primarily. After the first round of work, databases were switched among authors to ensure accuracy of literature search and selection. Disagreements were settled through discussion between the authors. The studies were subjected to 3-phase selection. Titles were screened in the first round, abstracts in the second round, and full-texts in the third round. The most recent study was considered in the case of duplicate or overlapping population studies.
Studies were eligible for inclusion if they contained original data on number of patients, lag between the onset of symptoms and first physician visit or lag between initial visit and rheumatology referral, or lag from referral to diagnosis and/or lag from diagnosis to the initiation of DMARDs. Papers analyzing the significance of factors contributing to these lags in RA patients were selected toward the secondary objective of this review. Studies satisfying the above criteria were eligible for inclusion, irrespective of demographic, geographic, or design variations.
Lag times were not reported uniformly among papers. For example, some considered lag1 as the time from onset to first medical encounter while others considered it as the time from first medical encounter until referral to rheumatologist, and so on. Many studies reported a single time lag (eg, from onset to diagnosis) and provided no further details. Some studies reported lag time in weeks and others in months. Some articles compared the results of 2 or more studies that were performed under similar settings but in 2 different time periods followed by comparison of lag times. Descriptive presentation also varied as some studies reported lag time as averages while others reported the median values. Except for the mean and median issue, we resolved other issues by setting our own definitions of lag times, namely lag1 as the time from onset of symptoms to seeking first medical consulOpen Access Rheumatology: Research and Reviews 2017:9 submit your manuscript | www.dovepress.com
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The journey of rheumatoid arthritis patients tation; lag2 as time from seeking medical consultation until referral to rheumatologist; lag3 as the time from referral to definite RA diagnosis, and lag4 as the time from diagnosis to the initiation of DMARDs.
If detailed lag times were not reported in any study, but only a single lag time with a specific start and end points, cells in the corresponding row on the table were merged according to the start and end points specified in that study. We used months as time unit uniformly. Whenever the lag times were reported in weeks and days, we converted them into months. In the case of comparative studies, we only reported data from the latest studies.
For the mean and median issue, when calculating the total lag time, we included only studies that had reported the delay in mean and SD value in the calculation of the total lag times.
Results and discussion
The initial literature search returned 363 titles. After screening of titles for eliminating duplicates and irrelevant studies, we were left with 150 studies. Ninety-five studies were eliminated in the next stage after abstract and full-text screening ( Figure 1) . Out of these, 37 studies were relevant to 1 or multiple variables of our primary objective, and 18 studies were relevant to our secondary objective. Data from these papers were extracted and reviewed.
The full-text papers from the first and second category were reviewed. Studies that were only available as informative abstracts were included if complete data on the number of subjects and lag time were provided, even if published in non-English languages. Table 1 outlines the main data from the eligible studies. Twelve studies reported the total lag time from the onset of symptoms to the initiation of DMARD therapy. The weighted average of median lag time of 5,512 patients from the onset of symptoms to therapy was 11.79 months with a range of 3.6-24.0 months (Figure 2 ). [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Lag1 data were also available from 12 studies on a total of 6,055 RA patients. The weighted average of median lag time from the onset of symptoms to the first physician consultation was 3.41 months with a range of 0-5.7 months. 17, 20, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] Lag2 data were available from 13 studies on a total of 34,767 RA patients. The weighted average of median lag time for RA specialist referral after consulting a physician was 2.13 months with a range of 0.5-6.6 months. 17, 20, 22, 25, 26, [29] [30] [31] [33] [34] [35] [36] [37] Lag3 data were available from 3 studies on a total of 563 RA patients. The weighted average of median lag time for the diagnosis of RA after consulting a rheumatologist was 2.91 months with a range of 0-5 months. 16, 17, 21 Lag4 data were available from 5 studies on a total of 30,685 RA patients. The weighted average of median lag time for initiation of DMARD therapy after definite diagnosis of RA was 2.14 months with a range of 0-2.2 months. 16, 17, 20, 24, 37 Early RA diagnosis and gaps in care
The understanding of "early" RA is heterogeneous. Two of 3 rheumatologists use the term "early" for symptoms shorter than 3 months. The vast majority of the rheumatologists surveyed regard symptom duration of <3 months as early. 38 Evidence is accumulating that very early RA (within the first 12 weeks) may be an immunopathologically distinct phase of disease. Thus, a "window of opportunity" may exist during which introducing DMARDs may have different effects than treatment at a later date, including prevention of erosions and possibly complete switching off of the disease. 39 It was found that the strongest predictor of improvements in disease activity (according to the American College of Rheumatology definition) was shorter disease duration at the start of treatment. 39 Gaps in care begin with the person's recognition of the symptoms and the action of visiting a family physician (FP). If RA is suspected, the FP refers the person to a rheumatologist who provides diagnosis and prescribes appropriate 
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Barhamain et al medications. Next, the person will be periodically assessed by a rheumatologist. Studies performed in the past 2 decades which evaluate the onset of DMARDs treatment in patients with early RA, performed in the USA, Spain, Canada, the UK, the Middle East, and in European countries, show that the mean time since the onset of disease and the onset of disease-modifying antirheumatic treatment ranges from 6 to 18 months. 22 This indicates that the diagnosis of RA after the onset of symptoms is delayed, and therefore, the objective of starting treatment early is not achieved in most of the cases.
Causes of delay
Delay is probably due to a combination of patient-related and physician-related factors. We reviewed 17 papers and analyzed factors contributing to the delay in care for RA patients ( Table 2) .
The results of a recent study published in 2014 evaluating the time since the beginning of disease and the visit to the FP, the time since this and the referral to the rheumatologist, and the time to onset of DMARD treatment, 22 showed that only in 19% of patients, DMARDs were started in the first 3 months after disease onset and that the delay in the prescription of DMARDs was mainly due to the delay in referral from family medicine to the rheumatologist.
In addition to the assumption of incompetency and poor knowledge, a qualitative research among osteoarthritis (OA) and RA patients in Germany, France, Spain, UK, and Italy revealed that for the majority of interviewed patients, their general practitioner visit is rated as disappointing due to poor communication and a focus merely on pain control. The journey that a patient undergoes before seeking medical advice is frequently long and emotionally exhausting. 40 Delay in the diagnosis and management of RA may stem from slow diagnosis by physicians rather than postponed medical consultation by patients. This may be because patients with RA often do not seek the advice of rheumatologists at the onset of their symptoms and non-rheumatologists fail to refer RA patients to rheumatologists soon enough. In Saudi Arabia, although patients consulted with physicians at a mean of 7 months after the onset of RA symptoms, very few subjects initially sought a consultation with rheumatologists, who were ultimately responsible for diagnosing most RA patients.
14 It is thus believed that delayed specialist included: -a sudden and severe symptom onset -symptoms resistant to self-management strategies -symptoms not easing -symptoms disrupting daily activities -the perception that symptoms were unusual and could not be explained 2. Numbers of patients were trying to identify external causative factors, or felt that joint pain and stiffness were simply part of getting older and as a result they would delay or avoid seeking medical attention. Others mentioned "knocks" and other injuries as a possible cause, specifically when experiencing symptoms in a single joint. They would delay help-seeking if they suspected injury as a causal factor 3. RA patients interviewed within a year of diagnosis, described using over-thecounter medications prior to, or instead of, seeking medical advice or while awaiting a formal diagnosis 
Possible interventions
It is necessary to implement measures that act on early diagnosis and treatment of RA, through the diffusion of knowledge relating to the disease in the general population, advertising campaigns as well as an increase in the level of knowledge regarding RA in primary care physicians.
Successful intervention is largely dependent on the availability of local programs and the coordination among the rheumatologist, the FP, and other health professionals. Moving from one level of care to the next involves a potential wait period. 41 A 2013 systematic literature review addressed and identified 3 main areas of delay to care for patients with inflammatory arthritis (IA) and potential solutions. 42 From the onset of symptoms to primary care, several websites provided informaOpen Access Rheumatology: Research and Reviews 2017:9 submit your manuscript | www.dovepress.com
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Barhamain et al tion but were of varying quality and insufficient to aid early referral. At a primary care level, many guidelines emphasized the need for early referral with providing specific referral criteria. 39, 43 Once referred, early arthritis clinics provided a point of early access to rheumatology assessment. Triage systems, including triage clinics, helped prioritizing clinic appointments for patients with IA. Use of referral forms standardized the information required, further optimizing the triage process.
Guidelines for early referral are needed. 38 Clinical criteria would facilitate early referral of the patient with suspected RA to a rheumatologist for definitive diagnosis and initiation of DMARD treatment. In a recently published study by Almoallim et al, 44 we have validated the variables that may aid in the design of referral criteria. These are based on musculoskeletal examination techniques to assess the presence of arthritis by primary care physicians in "target" joints; wrists, second and third metacarpophalangeals, and third proximal interphalangeal joints. 45 This is in addition to positive rheumatoid factor and anti-citrullinated protein antibody (anti-cyclic citrullinated peptide).
Key points of the referral criteria were formed based on literature review. Clinical evidence strongly supports the observations that rapid referral to a rheumatologist is advised when RA is suspected, which may be supported by the presence of any of the following: persistent joint swelling in more than 1 joint, early morning stiffness ≥30 minutes, or involvement of metacarpophalangeal or metatarsophalangeal joints. 39, 43 These criteria were mainly based on experts' opinion not on validated measures as in our unpublished work. Urgent referral (ideally within 6 weeks of symptom onset) to rheumatology should then be made with a clear indication that IA (or RA) is suspected. This should be done without waiting for the results of tests such as rheumatoid factor and plain radiographs, which are often normal in the early phase of disease. 39, 43 All rheumatologists should make it a priority to see patients with suspected IA on an urgent basis. Triage is important to facilitate early treatment; however, rheumatologists in this service are not currently triaging suspected RA referrals with reference to known poor prognostic indicators. 46 However, several interventions could improve both informative referrals and triaging of referrals to decrease time to diagnosis and treatment including public education, general practitioner education sessions with associated distribution of referral guidelines, and reminding triaging rheumatology clinicians about the available prognostic factors often present in general practitioner referrals that assist with correct triage. 46 
